These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 21995695

  • 1. Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study.
    Chung MS, Lee SH, Park KK, Yoo SJ, Chung BH.
    Int J Clin Pract; 2011 Nov; 65(11):1193-9. PubMed ID: 21995695
    [Abstract] [Full Text] [Related]

  • 2. Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study.
    Zhang K, Yu W, Jin J, Ye H, Wang X, Zhang N, Yang Y, Zhong C, Wan B.
    Urology; 2011 Sep; 78(3):636-40. PubMed ID: 21696807
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D, Soebadi DM, Sugandi S, Birowo P, Djati W, Wahyudi I.
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [Abstract] [Full Text] [Related]

  • 4. Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients.
    Xue Z, Zhang Y, Ding Q, He Z, Wang J, Xu K.
    Int J Urol; 2007 Feb; 14(2):118-22. PubMed ID: 17302567
    [Abstract] [Full Text] [Related]

  • 5. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.
    Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L.
    Eur Urol; 2012 May; 61(5):917-25. PubMed ID: 22297243
    [Abstract] [Full Text] [Related]

  • 6. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P, Kirby RS.
    Fortschr Med Orig; 2000 Jul 27; 118 Suppl 2():83-92. PubMed ID: 15700491
    [Abstract] [Full Text] [Related]

  • 7. A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil.
    Pompeo AC, Rosenblatt C, Bertero E, DA Ros CT, Cairoli CE, Damião R, Wroclawski ER, Koff WJ, Mesquita F, Pinheiro GE, Doxazosin and Tamsulosin Study Investigator Group.
    Int J Clin Pract; 2006 Oct 27; 60(10):1172-7. PubMed ID: 16942589
    [Abstract] [Full Text] [Related]

  • 8. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T.
    BJU Int; 2006 Apr 27; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [Abstract] [Full Text] [Related]

  • 9. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
    Lee SH, Chung BH, Kim SJ, Kim JH, Kim JC, Lee JY.
    Prostate Cancer Prostatic Dis; 2011 Dec 27; 14(4):320-5. PubMed ID: 21788967
    [Abstract] [Full Text] [Related]

  • 10. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
    Jhang JF, Jiang YH, Kuo HC.
    Int J Clin Pract; 2013 Dec 27; 67(12):1327-33. PubMed ID: 24246211
    [Abstract] [Full Text] [Related]

  • 11. Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.
    Chung BH, Hong SJ.
    BJU Int; 2006 Jan 27; 97(1):90-5. PubMed ID: 16336335
    [Abstract] [Full Text] [Related]

  • 12. Long-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): first-year follow-up report.
    Palacio A, Hernández C, Marqués A, Prats J, Espinosa FJ.
    Arch Esp Urol; 2004 May 27; 57(4):451-60. PubMed ID: 15270291
    [Abstract] [Full Text] [Related]

  • 13. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
    Yu HJ, Lin AT, Yang SS, Tsui KH, Wu HC, Cheng CL, Cheng HL, Wu TT, Chiang PH.
    BJU Int; 2011 Dec 27; 108(11):1843-8. PubMed ID: 21592295
    [Abstract] [Full Text] [Related]

  • 14. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z.
    BJU Int; 2008 Nov 27; 102(9):1133-9. PubMed ID: 18510659
    [Abstract] [Full Text] [Related]

  • 15. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
    de Reijke TM, Klarskov P.
    BJU Int; 2004 Apr 27; 93(6):757-62. PubMed ID: 15049986
    [Abstract] [Full Text] [Related]

  • 16. Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis.
    Kirby RS, Quinn S, Mallen S, Jensen D.
    Int J Clin Pract; 2004 Jan 27; 58(1):6-10. PubMed ID: 14994963
    [Abstract] [Full Text] [Related]

  • 17. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia.
    Kirby RS.
    BJU Int; 2003 Jan 27; 91(1):41-4. PubMed ID: 12614248
    [Abstract] [Full Text] [Related]

  • 18. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
    Suzuki H, Yano M, Awa Y, Nakatsu H, Egoshi K, Mikami K, Ota S, Okano T, Hamano S, Ohki T, Furuya Y, Ichikawa T.
    Int J Urol; 2006 Sep 27; 13(9):1202-6. PubMed ID: 16984553
    [Abstract] [Full Text] [Related]

  • 19. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.
    Montorsi F, Henkel T, Geboers A, Mirone V, Arrosagaray P, Morrill B, Black L.
    Int J Clin Pract; 2010 Jul 27; 64(8):1042-51. PubMed ID: 20487046
    [Abstract] [Full Text] [Related]

  • 20. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Gacci M, Vittori G, Tosi N, Siena G, Rossetti MA, Lapini A, Vignozzi L, Serni S, Maggi M, Carini M.
    J Sex Med; 2012 Jun 27; 9(6):1624-33. PubMed ID: 22510238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.